Navigation Links
Mylan Receives Approval for Generic Version of Neurontin® Tablets
Date:6/4/2010

PITTSBURGH, June 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of Pfizer's Neurontin® Tablets for the treatment of postherpetic neuralgia, a complication of shingles. The product will be distributed by Mylan Pharmaceuticals Inc.

Gabapentin Tablets had U.S. sales of approximately $174 million for the 12 months ending March 31, 2010, according to IMS Health.

Currently, Mylan has 140 ANDAs pending FDA approval representing $95.5 billion in annual brand sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing 21 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Valtrex®
2. Mylan Launches Temazepam Capsules USP, 7.5 mg
3. Mylan Announces Completion of Senior Notes Offering
4. Mylan Announces Upsizing and Pricing of Senior Notes
5. Mylan Announces Proposed Senior Notes Private Placement
6. Mylan Receives Approval for Generic Version of Zyban(R)
7. Mylan Receives Approval for Generic Version of Flomax(R)
8. Mylan Schedules First Quarter 2010 Financial Results Conference Call and Live Webcast
9. Mylan Receives Approval for Generic Version of Actigall(R)
10. Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
11. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 Summary This ... Bayer and its partnering interests and activities since 2010. ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ... The report will be delivered in PDF format within ...
(Date:3/27/2017)... -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced ... efficacy studies. The company is harnessing the power of ... A, in an effort to find a better treatment ... 4 weeks of treatment in transgenic mice, the lead ... a full toxicology report of various organs. Cytotoxic T-cells ...
(Date:3/27/2017)... 2017 To mark the end of Save Your ... leader in digital imaging solutions, will showcase Canon eye care ... New York,s Jacob Javits Center from ... sponsored by the American Optometric Association, is observed annually in ... comprehensive eye exams. In recognition of this observance, Canon ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... ... by physicians, announced today the launch of a free, public-facing tool for analyzing ... Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers and ...
(Date:3/28/2017)... ... , ... Usually, the impending arrival of warmer weather means the gleeful banishment ... double chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic ... double chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the ...
(Date:3/28/2017)... Conn. (PRWEB) , ... March 28, 2017 , ... ... based in Wethersfield, Conn., has relocated its corporate headquarters to a new, more ... clients. , In October 2016, Qualidigm purchased a distressed office building in ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the ... Association of Integrative Medicine and available for application on Saturday, May 27, 2017, ... Conference in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of ...
Breaking Medicine News(10 mins):